Apr 2, 2014

FDA Grants IND Approval For Phase 2a Clinical Trial Using CardioCell’s Itmsc Therapy To Treat Dilated Chronic Heart Failure

CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than 1 million hospitalizations annually. READ FULL ARTICLE